Medicinal cannabis is said to have a therapeutic effect on the body of those experiencing chronic pain or severe diseases. Studies are on the increase to examine what the future may hold for cannabinoids and their potential in the medical world. With CBD on the rise for treating patients with cancer, it is all the more interesting to examine what it could possibly do for other diseases and illnesses.
Here is the full scientific article if you wish to download it.
With a great collection of several hundreds of secondary metabolites discovered, Cannabis sativa L. (hemp) is one of the best described plant species. The biomedical importance of hemp undoubtedly outlines the great amount of data on its components and their biological actions. More so, to the well-known psychotropic abilities of THC, cannabinoids have been seen to show promise in various fields of medicine, with the ability to address unmet requirements like the alleviation of chemotherapy-derived nausea and anorexia, and symptomatic relief of multiple sclerosis.
Many of the possible therapeutic applications of cannabinoids are associated to the relationship with two cannabinoid receptors (CB1 and CB2). However, numerable activities, like the antibacterial or the antitumor abilities are not totally relying or fully individualistic from the relationship with these receptor proteins. These pharmacological abilities are specifically interesting since, in principle, they could be simply dissociated by the unwanted psychotropic adverse event.
Cannabinoids take away the thunder of the impact that natural products can have on modern medicinal chemistry and pharmacology. Almost one thousand experiment articles and a host of well-documented evaluations have been conjured up in the last three decades on this type of chemicals and their biomedical relevance. In retrospect, the clinical translation of this activity seems quite bad, since, apart from Sativex, THC, and its synthetic analogue nabilone, no other drug has come out of the woodwork from this research.
On the other hand, the difficulty inherent to the biological profile of these chemicals should also be taken into account, since, paralleled to other neuroactive chemicals, cannabinoids are exceedingly pleiotropic in their activity, while their receptors are part of difficult neural webs whose manipulation is too complex to predict in terms of in adverse side effects.